Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5)

Journal of Biological Chemistry

Volumn 289, Issue 41, 2014, Pages 28460-28477

  Haas, Laura T ^a,b   Kostylev, Mikhail A ^a   Strittmatter, Stephen M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; ANTIBODIES; CELL CULTURE; CELL MEMBRANES; ENZYME ACTIVITY; LIGANDS; MAMMALS; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION;

ALLOSTERIC MODULATORS; CELLULAR PRION PROTEINS; INTRACELLULAR SUBSTRATE; MEMBRANE PREPARATION; METABOTROPIC GLUTAMATE RECEPTORS; PROTEIN ASSOCIATIONS; THERAPEUTIC MOLECULES; THERAPEUTIC POTENTIALS;

ASSOCIATION REACTIONS;

3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 3,5 DIHYDROXYPHENYLGLYCINE; 4 BUTOXY N (2,4 DIFLUOROPHENYL)BENZAMIDE; 4 FLUOROPHENYL [3 [3 (4 FLUOROPHENYL) [1,2,4] OXADIAZOL 5 YL]PIPERIDIN 1 YL]METHANONE; 6 METHOXY N (4 METHOXYPHENYL) 4 QUINAZOLINAMINE; 6 METHYL 2 PHENYLAZO 3 PYRIDINOL; AMYLOID BETA PROTEIN; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 8; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; MYC PROTEIN; PRION PROTEIN; UNCLASSIFIED DRUG; ANTIBODY; LIGAND; MOLECULAR LIBRARY; PROTEIN BINDING; RECOMBINANT PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; FEMALE; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOASSAY; BRAIN LEVEL; CELL MEMBRANE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MOLECULAR LIBRARY; PATHOLOGY; PEPTIDE MAPPING; PHARMACOLOGY; PROTEIN TERTIARY STRUCTURE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES; BINDING SITES; BIOLOGICAL ASSAY; BRAIN CHEMISTRY; CELL MEMBRANE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; LIGANDS; MICE; MICE, TRANSGENIC; PEPTIDE MAPPING; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PRPC PROTEINS; RECEPTOR, METABOTROPIC GLUTAMATE 5; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84907896560     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.584342     Document Type: Article

References (75)

1. Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., Regan, C. M., Walsh, D. M., Sabatini, B. L., and Selkoe, D. J. (2008) Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842
2. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., and Selkoe, D. J. (2002) Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539
3. Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., and Ashe, K. H. (2006) A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352-357
4. Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., Finch, C. E., Krafft, G. A., and Klein, W. L. (1998) Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95, 6448-6453
5. Li, S., Hong, S., Shepardson, N. E., Walsh, D. M., Shankar, G. M., and Selkoe, D. (2009) Soluble oligomers of amyloid β protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62, 788-801
6. Palop, J. J., and Mucke, L. (2010) Amyloid-β-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 13, 812-818
7. Berman, D. E., Dall'Armi, C., Voronov, S. V., McIntire, L. B., Zhang, H., Moore, A. Z., Staniszewski, A., Arancio, O., Kim, T. W., and Di Paolo, G. (2008) Oligomeric amyloid-β peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism. Nat. Neurosci. 11, 547-554
8. Lue, L. F., Kuo, Y. M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., and Rogers, J. (1999) Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853-862
9. McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther, K., Bush, A. I., and Masters, C. L. (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860-866
10. Wang, J., Dickson, D. W., Trojanowski, J. Q., and Lee, V. M. (1999) The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 158, 328-337
11. Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., and Katzman, R. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572-580
12. Katzman, R., Terry, R., DeTeresa, R., Brown, T., Davies, P., Fuld, P., Renbing, X., and Peck, A. (1988) Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol. 23, 138-144
13. Dickson, D. W., Crystal, H. A., Bevona, C., Honer, W., Vincent, I., and Davies, P. (1995) Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging 16, 285-298; discussion 298-304
14. Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., and Strittmatter, S. M. (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 457, 1128-1132
15. Zou, W. Q., Xiao, X., Yuan, J., Puoti, G., Fujioka, H., Wang, X., Richardson, S., Zhou, X., Zou, R., Li, S., Zhu, X., McGeer, P. L., McGeehan, J., Kneale, G., Rincon-Limas, D. E., Fernandez-Funez, P., Lee, H. G., Smith, M. A., Petersen, R. B., and Guo, J. P. (2011) Amyloid-β42 interacts mainly with insoluble prion protein in the Alzheimer brain. J. Biol. Chem. 286, 15095-15105
16. Balducci, C., Beeg, M., Stravalaci, M., Bastone, A., Sclip, A., Biasini, E., Tapella, L., Colombo, L., Manzoni, C., Borsello, T., Chiesa, R., Gobbi, M., Salmona, M., and Forloni, G. (2010) Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein. Proc. Natl. Acad. Sci. U.S.A. 107, 2295-2300
17. Chen, S., Yadav, S. P., and Surewicz, W. K. (2010) Interaction between human prion protein and amyloid-β (Aβ) oligomers: role OF N-terminal residues. J. Biol. Chem. 285, 26377-26383
18. Gimbel, D. A., Nygaard, H. B., Coffey, E. E., Gunther, E. C., Laurén, J., Gimbel, Z. A., and Strittmatter, S. M. (2010) Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J. Neurosci. 30, 6367-6374
19. Um, J. W., Nygaard, H. B., Heiss, J. K., Kostylev, M. A., Stagi, M., Vortmeyer, A., Wisniewski, T., Gunther, E. C., and Strittmatter, S. M. (2012) Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 15, 1227-1235
20. Bate, C., and Williams, A. (2011) Amyloid-β-induced synapse damage is mediated via cross-linkage of cellular prion proteins. J. Biol. Chem. 286, 37955-37963
21. Kudo, W., Lee, H. P., Zou, W. Q., Wang, X., Perry, G., Zhu, X., Smith, M. A., Petersen, R. B., and Lee, H. G. (2012) Cellular prion protein is essential for oligomeric amyloid-β-induced neuronal cell death. Hum. Mol. Genet. 21, 1138-1144
22. Chung, E., Ji, Y., Sun, Y., Kascsak, R. J., Kascsak, R. B., Mehta, P. D., Strittmatter, S. M., and Wisniewski, T. (2010) Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci. 11, 130
23. Barry, A. E., Klyubin, I., McDonald, J. M., Mably, A. J., Farrell, M. A., Scott, M., Walsh, D. M., and Rowan, M. J. (2011) Alzheimer's disease brain-derived amyloid-β-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J. Neurosci. 31, 7259-7263
24. Freir, D. B., Nicoll, A. J., Klyubin, I., Panico, S., Mc Donald, J. M., Risse, E., Asante, E. A., Farrow, M. A., Sessions, R. B., Saibil, H. R., Clarke, A. R., Rowan, M. J., Walsh, D. M., and Collinge, J. (2011) Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites. Nat. Commun. 2, 336
25. Kessels, H. W., Nguyen, L. N., Nabavi, S., and Malinow, R. (2010) The prion protein as a receptor for amyloid-β. Nature 466, E3-E4; discussion E4-E5
26. Calella, A. M., Farinelli, M., Nuvolone, M., Mirante, O., Moos, R., Falsig, J., Mansuy, I. M., and Aguzzi, A. (2010) Prion protein and Aβ-related synaptic toxicity impairment. EMBO Mol. Med. 2, 306-314
27. Gandy, S., Simon, A. J., Steele, J. W., Lublin, A. L., Lah, J. J., Walker, L. C., Levey, A. I., Krafft, G. A., Levy, E., Checler, F., Glabe, C., Bilker, W. B., Abel, T., Schmeidler, J., and Ehrlich, M. E. (2010) Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-β oligomers. Ann. Neurol. 68, 220-230
28. Reed, M. N., Hofmeister, J. J., Jungbauer, L., Welzel, A. T., Yu, C., Sherman, M. A., Lesné, S., LaDu, M. J., Walsh, D. M., Ashe, K. H., and Cleary, J. P. (2011) Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiol. Aging 32, 1784-1794
29. Cheng, I. H., Scearce-Levie, K., Legleiter, J., Palop, J. J., Gerstein, H., Bien-Ly, N., Puoliväli, J., Lesné, S., Ashe, K. H., Muchowski, P. J., and Mucke, L. (2007) Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282, 23818-23828
30. Um, J. W., Kaufman, A. C., Kostylev, M., Heiss, J. K., Stagi, M., Takahashi, H., Kerrisk, M. E., Vortmeyer, A., Wisniewski, T., Koleske, A. J., Gunther, E. C., Nygaard, H. B., and Strittmatter, S. M. (2013) Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron 79, 887-902
31. Francesconi, A., Kumari, R., and Zukin, R. S. (2009) Regulation of group I metabotropic glutamate receptor trafficking and signaling by the caveolar/lipid raft pathway. J. Neurosci. 29, 3590-3602
32. Agostini, F., Dotti, C. G., Pérez-Cañamás, A., Ledesma, M. D., Benetti, F., and Legname, G. (2013) Prion protein accumulation in lipid rafts of mouse aging brain. PLoS ONE 8, e74244
33. Zampagni, M., Evangelisti, E., Cascella, R., Liguri, G., Becatti, M., Pensalfini, A., Uberti, D., Cenini, G., Memo, M., Bagnoli, S., Nacmias, B., Sorbi, S., and Cecchi, C. (2010) Lipid rafts are primary mediators of amyloid oxidative attack on plasma membrane. J. Mol. Med. 88, 597-608
34. Rushworth, J. V., Griffiths, H. H., Watt, N. T., and Hooper, N. M. (2013) Prion protein-mediated toxicity of amyloid-β oligomers requires lipid rafts and the transmembrane LRP1. J. Biol. Chem. 288, 8935-8951
35. Renner, M., Lacor, P. N., Velasco, P. T., Xu, J., Contractor, A., Klein, W. L., and Triller, A. (2010) Deleterious effects of amyloid β oligomers acting as an extracellular scaffold for mGluR5. Neuron 66, 739-754
36. Beraldo, F. H., Arantes, C. P., Santos, T. G., Machado, C. F., Roffe, M., Hajj, G. N., Lee, K. S., Magalhães, A. C., Caetano, F. A., Mancini, G. L., Lopes, M. H., Américo, T. A., Magdesian, M. H., Ferguson, S. S., Linden, R., Prado, M. A., and Martins, V. R. (2011) Metabotropic glutamate receptors transduce signals for neurite outgrowth after binding of the prion protein to laminin γ1 chain. FASEB J. 25, 265-279
37. Benarroch, E. E. (2008) Metabotropic glutamate receptors: synaptic modulators and therapeutic targets for neurologic disease. Neurology 70, 964-968
38. Rammes, G., Hasenjäger, A., Sroka-Saidi, K., Deussing, J. M., and Parsons, C. G. (2011) Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology 60, 982-990
39. Wang, Q., Walsh, D. M., Rowan, M. J., Selkoe, D. J., and Anwyl, R. (2004) Block of long-term potentiation by naturally secreted and synthetic amyloid β-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24, 3370-3378
40. Bruno, V., Ksiazek, I., Battaglia, G., Lukic, S., Leonhardt, T., Sauer, D., Gasparini, F., Kuhn, R., Nicoletti, F., and Flor, P. J. (2000) Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology 39, 2223-2230
41. Hu, N. W., Nicoll, A. J., Zhang, D., Mably, A. J., O'Malley, T., Purro, S. A., Terry, C., Collinge, J., Walsh, D. M., and Rowan, M. J. (2014) mGlu5 receptors and cellular prion protein mediate amyloid-β-facilitated synaptic long-term depression in vivo. Nat. Commun. 5, 3374
42. Larson, M., Sherman, M. A., Amar, F., Nuvolone, M., Schneider, J. A., Bennett, D. A., Aguzzi, A., and Lesné, S. E. (2012) The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological Tau changes in Alzheimer's disease. J. Neurosci. 32, 16857-16871a
43. Antonyuk, S. V., Trevitt, C. R., Strange, R. W., Jackson, G. S., Sangar, D., Batchelor, M., Cooper, S., Fraser, C., Jones, S., Georgiou, T., Khalili-Shirazi, A., Clarke, A. R., Hasnain, S. S., and Collinge, J. (2009) Crystal structure of human prion protein bound to a therapeutic antibody. Proc. Natl. Acad. Sci. U.S.A. 106, 2554-2558
44. Wu, H., Wang, C., Gregory, K. J., Han, G. W., Cho, H. P., Xia, Y., Niswender, C. M., Katritch, V., Meiler, J., Cherezov, V., Conn, P. J., and Stevens, R. C. (2014) Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science 344, 58-64
45. Muto, T., Tsuchiya, D., Morikawa, K., and Jingami, H. (2007) Structures of the extracellular regions of the group II/III metabotropic glutamate receptors. Proc. Natl. Acad. Sci. U.S.A. 104, 3759-3764
46. Jankowsky, J. L., Xu, G., Fromholt, D., Gonzales, V., and Borchelt, D. R. (2003) Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J. Neuropathol. Exp. Neurol. 62, 1220-1227
47. Lu, Y. M., Jia, Z., Janus, C., Henderson, J. T., Gerlai, R., Wojtowicz, J. M., and Roder, J. C. (1997) Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J. Neurosci. 17, 5196-5205
48. O'Brien, J. A., Lemaire, W., Chen, T. B., Chang, R. S., Jacobson, M. A., Ha, S. N., Lindsley, C. W., Schaffhauser, H. J., Sur, C., Pettibone, D. J., Conn, P. J., and Williams, D. L., Jr. (2003) A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol. Pharmacol. 64, 731-740
49. Rondard, P., Goudet, C., Kniazeff, J., Pin, J. P., and Prézeau, L. (2011) The complexity of their activation mechanism opens new possibilities for the modulation of mGlu and GABAB class C G protein-coupled receptors. Neuropharmacology 60, 82-92
50. Schwartz, T. W., Frimurer, T. M., Holst, B., Rosenkilde, M. M., and Elling, C. E. (2006) Molecular mechanism of 7TM receptor activation: a global toggle switch model. Annu. Rev. Pharmacol. Toxicol. 46, 481-519
51. Ribeiro, F. M., Paquet, M., Cregan, S. P., and Ferguson, S. S. (2010) Group I metabotropic glutamate receptor signalling and its implication in neurological disease. CNS Neurol. Disord. Drug Targets 9, 574-595
52. Pin, J. P., and Duvoisin, R. (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34, 1-26
53. Lüscher, C., and Huber, K. M. (2010) Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease. Neuron 65, 445-459
54. Um, J. W., and Strittmatter, S. M. (2013) Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease. Prion 7, 37-41
55. Yusa, S., Oliveira-Martins, J. B., Sugita-Konishi, Y., and Kikuchi, Y. (2012) Cellular prion protein: from physiology to pathology. Viruses 4, 3109-3131
56. Pin, J. P., Galvez, T., and Prézeau, L. (2003) Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol. Ther. 98, 325-354
57. Gregory, K. J., Dong, E. N., Meiler, J., and Conn, P. J. (2011) Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology 60, 66-81
58. Sheffler, D. J., Gregory, K. J., Rook, J. M., and Conn, P. J. (2011) Allosteric modulation of metabotropic glutamate receptors. Adv. Pharmacol. 62, 37-77
59. Gasparini, F., and Spooren, W. (2007) Allosteric modulators for mGlu receptors. Curr. Neuropharmacol. 5, 187-194
60. Gregory, K. J., Noetzel, M. J., Rook, J. M., Vinson, P. N., Stauffer, S. R., Rodriguez, A. L., Emmitte, K. A., Zhou, Y., Chun, A. C., Felts, A. S., Chauder, B. A., Lindsley, C. W., Niswender, C. M., and Conn, P. J. (2012) Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships. Mol. Pharmacol. 82, 860-875
61. Molck, C., Harpsoe, K., Gloriam, D. E., Mathiesen, J. M., Nielsen, S. M., and Brauner-Osborne, H. (2014) mGluR5: exploration of orthosteric and allosteric ligand binding pockets and their applications to drug discovery. Neurochem. Res. 10.1007/s11064-014-1248-8
62. Bruno, V., Battaglia, G., Copani, A., D'Onofrio, M., Di Iorio, P., De Blasi, A., Melchiorri, D., Flor, P. J., and Nicoletti, F. (2001) Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J. Cereb. Blood Flow Metab. 21, 1013-1033
63. Trevitt, C. R., and Collinge, J. (2006) A systematic review of prion therapeutics in experimental models. Brain 129, 2241-2265
64. Xu, J., Zhu, Y., Contractor, A., and Heinemann, S. F. (2009) mGluR5 has a critical role in inhibitory learning. J. Neurosci. 29, 3676-3684
65. Wis̈niewski, K., and Car, H. (2002) (S)-3,5-DHPG: a review. CNS Drug Rev. 8, 101-116
66. Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., Möbius, H. J., and Memantine Study Group. (2003) Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348, 1333-1341
67. Lipton, S. A. (2005) The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr. Alzheimer Res. 2, 155-165
68. Sergé, A., Fourgeaud, L., Hémar, A., and Choquet, D. (2002) Receptor activation and homer differentially control the lateral mobility of metabotropic glutamate receptor 5 in the neuronal membrane. J. Neurosci. 22, 3910-3920
69. Rosenmund, C., Feltz, A., and Westbrook, G. L. (1995) Calcium-dependent inactivation of synaptic NMDA receptors in hippocampal neurons. J. Neurophysiol. 73, 427-430
70. Mao, L., Yang, L., Tang, Q., Samdani, S., Zhang, G., and Wang, J. Q. (2005) The scaffold protein Homer1b/c links metabotropic glutamate receptor 5 to extracellular signal-regulated protein kinase cascades in neurons. J. Neurosci. 25, 2741-2752
71. Hou, L., and Klann, E. (2004) Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J. Neurosci. 24, 6352-6361
72. Tu, J. C., Xiao, B., Naisbitt, S., Yuan, J. P., Petralia, R. S., Brakeman, P., Doan, A., Aakalu, V. K., Lanahan, A. A., Sheng, M., and Worley, P. F. (1999) Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23, 583-592
73. Leclerc, E., Liemann, S., Wildegger, G., Vetter, S. W., and Nilsson, F. (2000) Selection and characterization of single chain Fv fragments against murine recombinant prion protein from a synthetic human antibody phage display library. Hum. Antibodies 9, 207-214
74. Féraudet, C., Morel, N., Simon, S., Volland, H., Frobert, Y., Créminon, C., Vilette, D., Lehmann, S., and Grassi, J. (2005) Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells. J. Biol. Chem. 280, 11247-11258
75. Spinner, D. S., Kascsak, R. B., Lafauci, G., Meeker, H. C., Ye, X., Flory, M. J., Kim, J. I., Schuller-Levis, G. B., Levis, W. R., Wisniewski, T., Carp, R. I., and Kascsak, R. J. (2007) CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils. J. Leukocyte Biol. 81, 1374-1385